PMID- 33113888
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 13
IP  - 11
DP  - 2020 Oct 23
TI  - The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced 
      Lung Adenocarcinoma: A Multicenter Observational Study.
LID - 10.3390/ph13110331 [doi]
LID - 331
AB  - The efficacy of afatinib in combination with bevacizumab in untreated advanced 
      epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma is currently 
      unclear. We sought to investigate the efficacy of this combination through a 
      multicenter observational analysis. Data for 57 patients with advanced 
      EGFR-mutated lung adenocarcinoma who received afatinib combined with bevacizumab 
      as first-line therapy at the Chang Gung Memorial Hospitals in Linkou and 
      Kaohsiung and Taipei Tzu Chi Hospital from May 2015 to July 2019 were analyzed. 
      The objective response rate and disease control rate of afatinib combined with 
      bevacizumab therapy were 87.7% and 100%, respectively. In all patients, the 
      median progression-free survival (PFS) and overall survival (OS) were 23.9 (95% 
      confidence interval (CI) (17.56-29.17)) and 45.9 (95% CI (39.50-53.60)) months, 
      respectively. No statistical significance between exon 19 deletion and L858R 
      mutations was noted in PFS or OS. The most frequent adverse events (AEs) were 
      diarrhea (98.2%) and dermatitis (96.5%), and most AEs were grade 2 or lower and 
      manageable. The combination of afatinib and bevacizumab is an effective therapy 
      for untreated advanced EGFR-mutated lung adenocarcinoma with acceptable safety. 
      Future prospective studies focusing on this combination for untreated advanced 
      EGFR-mutated lung adenocarcinoma are warranted.
FAU - Hsu, Ping-Chih
AU  - Hsu PC
AUID- ORCID: 0000-0003-0173-7509
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
AD  - Department of Thoracic Medicine, New Taipei Municipal Tu Cheng Hospital, Chang 
      Gung Memorial Hospital and Chang Gung University, New Taipei City 23652, Taiwan.
FAU - Huang, Chun-Yao
AU  - Huang CY
AD  - Department of Pulmonary and Critical Care, Buddhist Tzu Chi General Hospital, 
      Taipei Branch, New Taipei City 231405, Taiwan.
FAU - Wang, Chin-Chou
AU  - Wang CC
AD  - Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial 
      Hospital, Kaohsiung City 83301, Taiwan.
FAU - Kuo, Scott Chih-Hsi
AU  - Kuo SC
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
FAU - Chu, Chia-Hsun
AU  - Chu CH
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
FAU - Tung, Pi-Hung
AU  - Tung PH
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
FAU - Huang, Allen Chung-Cheng
AU  - Huang AC
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
FAU - Wang, Chih-Liang
AU  - Wang CL
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
FAU - Chiu, Li-Chung
AU  - Chiu LC
AUID- ORCID: 0000-0003-1660-7715
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
AD  - Department of Thoracic Medicine, New Taipei Municipal Tu Cheng Hospital, Chang 
      Gung Memorial Hospital and Chang Gung University, New Taipei City 23652, Taiwan.
FAU - Fang, Yueh-Fu
AU  - Fang YF
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
FAU - Yang, Cheng-Ta
AU  - Yang CT
AUID- ORCID: 0000-0003-1846-1027
AD  - Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 
      City 33305, Taiwan.
AD  - Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan 
      City 33378, Taiwan.
AD  - Department of Respiratory Therapy, College of Medicine, Chang Gung University, 
      Taoyuan City 33302, Taiwan.
LA  - eng
GR  - 108-2314-B-182A-133-/Ministry of Science and Technology, Taiwan/
GR  - 109-2628-B-182A-009-/Ministry of Science and Technology, Taiwan/
GR  - CMRPG5H0141/Chang-Gung Medical Research Project/
GR  - CMRPG3D1891/Chang-Gung Medical Research Project/
GR  - CMRPG3D1892/Chang-Gung Medical Research Project/
GR  - CMRPG3D1893/Chang-Gung Medical Research Project/
PT  - Journal Article
DEP - 20201023
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC7690705
OTO - NOTNLM
OT  - afatinib
OT  - anti-angiogenesis
OT  - bevacizumab
OT  - epidermal growth factor receptor (EGFR)
OT  - lung adenocarcinoma
OT  - tyrosine kinase inhibitor (TKI)
COIS- All authors have no conflicts of interest.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
PMCR- 2020/11/01
CRDT- 2020/10/29 01:02
PHST- 2020/09/29 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/10/29 01:02 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - ph13110331 [pii]
AID - pharmaceuticals-13-00331 [pii]
AID - 10.3390/ph13110331 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2020 Oct 23;13(11):331. doi: 10.3390/ph13110331.